Sekar Kathiresan, Chief Executive Officer at Verve Therapeutics, Inc. (VERV), sold 171,000 shares at $39.90 ($6.7M) on 2021-12-23, disclosed to the SEC on 2021-12-27.
Open-market sale of $6.7M VERV by Chief Executive Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Something here stands out, but not much.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $37.38 | 5,874 | $220K | 3.3% |
| 2 | $37.38 | 5,874 | $220K | 3.3% |
| 3 | $38.31 | 16,718 | $640K | 9.6% |
| 4 | $38.31 | 16,718 | $640K | 9.6% |
| 5 | $39.06 | 31,139 | $1.2M | 18.2% |
| 6 | $39.06 | 31,139 |
| $1.2M |
| 18.2% |
| 7 | $39.78 | 3,269 | $130K | 1.9% |
| 8 | $39.78 | 3,269 | $130K | 1.9% |
| 9 | $39.90 | 57,000 | $2.3M | 34.0% |
| Total | $39.11 avg | 171,000 | $6.7M | 100% |
| Filing → |
| VERV | SELL | 2022-08-11 | $1.5M | — | Filing → |
| VERV | SELL | 2022-07-21 | $1.5M | — | Filing → |
| VERV | SELL | 2022-01-06 | $75K | — | Filing → |